U.S., Nov. 15 -- ClinicalTrials.gov registry received information related to the study (NCT07228442) titled 'L19IL2/L19TNF in Patients With Cutaneous Squamous Cell Carcinoma' on Nov. 07.
Brief Summary: Open-label, single-arm, multicenter study in patients with locally advanced, histologically confirmed Cutaneous Squamous Cell Carcinoma (LacSCC) amenable to intratumoral injection, who have progressed on or are intolerant to Immune Checkpoint Inhibitor (ICI). The primary objective of the study is to evaluate the activity of intratumoral L19IL2/L19TNF, while the secondary objective is to assess the safety and efficacy. The patients will receive multiple intratumoral administrations of combined L19IL2 and L19TNF to all injectable cutaneous and...